Regeneron Pharmaceuticals (REGN) 416.44 $REGN
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 157.12 (-2.03), SWX: 57.19 (-1.09), HON: 95.88 (-2.01), NKE: 96.17 (-0.76), CHTR: 162.95 (-1.21), BBRY: 9.84 (-0.32), XON: 27.01 (+0.35), RMTI: 8.20 (+0.04), KMX: 58.30 (-1.21), MEMP: 13.13 (-0.96), ACAD: 32.53 (-0.10), PAYX: 46.10 (-0.77), AGU: 91.53 (-2.47), TRUE: 21.35 (-1.68), LOW: 64.87 (-0.89), TWTR: 37.10 (+0.40), REGN: 416.44 (-7.91), JOY: 46.28 (-2.80), FDX: 175.79 (-1.09), LBRDA: 49.07 (-1.58), FINL: 28.32 (+0.15), ORCL: 39.95 (-0.81), DRI: 57.38 (-0.45), BAX: 71.77 (-1.34), RHT: 57.87 (-0.55), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47), PG: 89.55 (-0.86)
Regeneron Pharmaceuticals Becomes #26 Most Shorted Nasdaq 100 Component, Replacing Micron Technology
MarketNewsVideo.com - Thu Dec 11, 3:21PM CST
The most recent short interest data has been released by the NASDAQ for the 11/28/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
REGN: 416.44 (-7.91)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 7.99 (-0.16), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
Adaptive Asset Allocation: Experimentation With A Large Stock Portfolio
Toma Hentea - at Seeking Alpha - Wed Dec 10, 12:53PM CST
URTY: 82.16 (-3.19), TSLA: 207.00 (-1.88), GPRO: 60.52 (+0.47), WBMD: 36.55 (-0.18), DDD: 30.00 (-0.59), FB: 77.83 (+0.10), VFC: 72.68 (-0.65), XOM: 86.60 (-2.60), WFC: 53.70 (-0.73), TM: 124.54 (-1.55), KORS: 76.97 (+0.27), INTC: 36.22 (-0.48), CELG: 114.49 (-2.25), YHOO: 50.24 (+0.30), TJX: 65.61 (+0.01), LOW: 64.87 (-0.89), CAT: 90.50 (-2.19), TASR: 23.19 (unch), CVX: 102.38 (-2.53), MSFT: 46.95 (-0.22), AAPL: 109.73 (-1.89), UNP: 112.55 (-1.80), REGN: 416.44 (-7.91), CREE: 30.16 (-0.17)
3 Biotech Stocks to Buy in December
Motley Fool Staff - Motley Fool - Wed Dec 10, 8:18AM CST
Source: Biogen Idec As the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will...
BIIB: 344.49 (+2.16), SNY: 45.16 (-1.05), ANIK: 37.48 (-1.23), REGN: 416.44 (-7.91)
5 Biotech Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 09, 3:44PM CST
Source: Celgene Corporation The biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn't necessarily mean that they'll rally next...
MDVN: 106.86 (-1.16), BMRN: 91.52 (-1.38), GILD: 104.13 (-0.18), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Regeneron Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.77%
Comtex SmarTrend(R) - Mon Dec 08, 5:29PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $421.83 to a high of $437.64. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $427.78 on volume of 580,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 416.44 (-7.91)
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low
at The Street - Mon Dec 08, 3:24PM CST
Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), TOT: 50.12 (-1.10), MRK: 57.72 (-1.62), BP: 36.24 (-1.09), CVX: 102.38 (-2.53), REGN: 416.44 (-7.91), XLE: 74.02 (-1.40)
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt
at The Street - Mon Dec 08, 2:30PM CST
Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), RIG: 16.47 (-0.55), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83), XLE: 74.02 (-1.40)
Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 46.33 (-1.64), GPRO: 60.52 (+0.47), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), UTHR: 129.37 (-1.86), MCD: 90.62 (-0.35), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
at The Street - Mon Dec 08, 10:04AM CST
Stocks trade flat as a rally in pharmaceuticals trumps a selloff in oil-related companies and plunging crude prices.
VRTX: 118.55 (-2.23), COP: 62.45 (-1.16), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), CBST: 96.31 (+0.04), EBAY: 55.77 (-1.01), RIG: 16.47 (-0.55), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
at The Street - Fri Dec 05, 11:18AM CST
TheStreet's Jim Cramer says Gilead Sciences may finally start to catch up to its peers, based on a research report from J.P. Morgan.
BIIB: 344.49 (+2.16), GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
at The Street - Fri Dec 05, 5:00AM CST
Cramer wants you to avoid Plug Power and Peabody Energy but would buy Molson Coors and Constellation Brands.
BIIB: 344.49 (+2.16), GPRO: 60.52 (+0.47), DRE: 19.30 (-0.27), ALU: 3.35 (-0.08), PLUG: 2.93 (-0.17), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HPQ: 38.01 (-0.46), VTR: 74.44 (+0.77), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), BTU: 7.37 (-0.04), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01)
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Dec 05, 3:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday December 4. Bullish Calls: Constellation Brands (NYSE: STZ ): "That is my favorite. It has Corona and Modelo. It has real magic." ...
GPRO: 60.52 (+0.47), BIIB: 344.49 (+2.16), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), VTR: 74.44 (+0.77), CELG: 114.49 (-2.25), BTU: 7.37 (-0.04), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), CSCO: 26.85 (-0.14), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), BIIB: 344.49 (+2.16), GD: 137.41 (-4.99), GE: 24.89 (-0.52), CAG: 36.73 (-0.56), STKL: 11.04 (-0.29), VTR: 74.44 (+0.77), TWX: 82.12 (-1.19), SBUX: 83.25 (+0.13), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), IDT: 18.09 (-0.33), COST: 137.88 (-3.53), DG: 69.80 (+0.65), GOOGL: 521.51 (-10.60), TRAK: 44.56 (-0.35), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01), AMZN: 307.32 (-0.04), GPRO: 60.52 (+0.47), HD: 99.78 (-0.49), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), FB: 77.83 (+0.10), SLXP: 103.36 (-2.79), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HABT: 41.89 (+0.55), FCAU: 11.36 (+0.18), BMY: 58.75 (-0.93), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), UA: 68.83 (+0.30), BTU: 7.37 (-0.04), LB: 83.39 (+0.24), ESV: 27.04 (-0.80), GILD: 104.13 (-0.18), VALE: 7.19 (-0.07), TXN: 53.11 (-1.38), MRO: 25.45 (-0.80), BAS: 5.22 (+0.05), CVX: 102.38 (-2.53), BABA: 105.11 (+0.14)
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:15AM CST
Shares of Regeneron have been riding high after the company announced that its supplemental biologics license application for Eylea will be reviewed by the FDA on a priority basis.
AMGN: 164.53 (-1.55), AMAG: 40.04 (-0.79), REGN: 416.44 (-7.91)
Ablexis Announces Availability of the AlivaMab Mouse Technology and Settlement of the Litigation with Regeneron Pharmaceuticals, Inc.
Business Wire - Thu Dec 04, 7:00AM CST
Ablexis, LLC today announced the completion and delivery to its licensees of its AlivaMab Mouse technology, an innovative and unique platform for discovery of the next generation of breakthrough human antibody drugs. The delivery of the AlivaMab Mouse technology to licensees earlier in 2014 enabled their deployment of the technology broadly throughout their respective organizations, providing non-exclusive long-term access with no target or field of use limitations, and fulfilling the needs of these companies for an improved transgenic platform for therapeutic antibody discovery. The AlivaMab Mouse technology remains available for non-exclusive licensing and immediate delivery.
REGN: 416.44 (-7.91)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 344.49 (+2.16), HON: 95.88 (-2.01), UTX: 112.15 (-1.89), KMB: 112.68 (-1.36), INTC: 36.22 (-0.48), PVH: 127.03 (+1.47), SLB: 80.00 (-3.01), PEP: 94.74 (-1.55), GWPH: 72.41 (+1.18), EOG: 86.37 (-0.49), REGN: 416.44 (-7.91), CSCO: 26.85 (-0.14), MU: 34.00 (-1.19), SWKS: 69.10 (-0.98), HAL: 37.93 (-0.30), SN: 6.95 (-0.13), BMY: 58.75 (-0.93), BA: 120.77 (-2.60), HPQ: 38.01 (-0.46), CELG: 114.49 (-2.25), ZTS: 41.77 (-1.11), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), JCP: 6.38 (+0.29), PG: 89.55 (-0.86), PAY: 33.01 (-1.47), SWHC: 9.60 (-0.03)
Jim Cramer on the Stock Market: You Have to Love Biotech
at The Street - Wed Dec 03, 11:29AM CST
In this era of turmoil, investors can take comfort in this sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), AMGN: 164.53 (-1.55), AGIO: 119.56 (+0.36), REGN: 416.44 (-7.91), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 157.12 (-2.03), SWX: 57.19 (-1.09), HON: 95.88 (-2.01), NKE: 96.17 (-0.76), CHTR: 162.95 (-1.21), BBRY: 9.84 (-0.32), XON: 27.01 (+0.35), RMTI: 8.20 (+0.04), KMX: 58.30 (-1.21), MEMP: 13.13 (-0.96), ACAD: 32.53 (-0.10), PAYX: 46.10 (-0.77), AGU: 91.53 (-2.47), TRUE: 21.35 (-1.68), LOW: 64.87 (-0.89), TWTR: 37.10 (+0.40), REGN: 416.44 (-7.91), JOY: 46.28 (-2.80), FDX: 175.79 (-1.09), LBRDA: 49.07 (-1.58), FINL: 28.32 (+0.15), ORCL: 39.95 (-0.81), DRI: 57.38 (-0.45), BAX: 71.77 (-1.34), RHT: 57.87 (-0.55), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47), PG: 89.55 (-0.86)
Regeneron Pharmaceuticals Becomes #26 Most Shorted Nasdaq 100 Component, Replacing Micron Technology
MarketNewsVideo.com - Thu Dec 11, 3:21PM CST
The most recent short interest data has been released by the NASDAQ for the 11/28/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." ...
REGN: 416.44 (-7.91)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 7.99 (-0.16), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
Adaptive Asset Allocation: Experimentation With A Large Stock Portfolio
Toma Hentea - at Seeking Alpha - Wed Dec 10, 12:53PM CST
URTY: 82.16 (-3.19), TSLA: 207.00 (-1.88), GPRO: 60.52 (+0.47), WBMD: 36.55 (-0.18), DDD: 30.00 (-0.59), FB: 77.83 (+0.10), VFC: 72.68 (-0.65), XOM: 86.60 (-2.60), WFC: 53.70 (-0.73), TM: 124.54 (-1.55), KORS: 76.97 (+0.27), INTC: 36.22 (-0.48), CELG: 114.49 (-2.25), YHOO: 50.24 (+0.30), TJX: 65.61 (+0.01), LOW: 64.87 (-0.89), CAT: 90.50 (-2.19), TASR: 23.19 (unch), CVX: 102.38 (-2.53), MSFT: 46.95 (-0.22), AAPL: 109.73 (-1.89), UNP: 112.55 (-1.80), REGN: 416.44 (-7.91), CREE: 30.16 (-0.17)
3 Biotech Stocks to Buy in December
Motley Fool Staff - Motley Fool - Wed Dec 10, 8:18AM CST
Source: Biogen Idec As the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will...
BIIB: 344.49 (+2.16), SNY: 45.16 (-1.05), ANIK: 37.48 (-1.23), REGN: 416.44 (-7.91)
5 Biotech Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 09, 3:44PM CST
Source: Celgene Corporation The biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn't necessarily mean that they'll rally next...
MDVN: 106.86 (-1.16), BMRN: 91.52 (-1.38), GILD: 104.13 (-0.18), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Regeneron Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.77%
Comtex SmarTrend(R) - Mon Dec 08, 5:29PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $421.83 to a high of $437.64. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $427.78 on volume of 580,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 416.44 (-7.91)
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low
at The Street - Mon Dec 08, 3:24PM CST
Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), TOT: 50.12 (-1.10), MRK: 57.72 (-1.62), BP: 36.24 (-1.09), CVX: 102.38 (-2.53), REGN: 416.44 (-7.91), XLE: 74.02 (-1.40)
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt
at The Street - Mon Dec 08, 2:30PM CST
Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), RIG: 16.47 (-0.55), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83), XLE: 74.02 (-1.40)
Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 46.33 (-1.64), GPRO: 60.52 (+0.47), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), UTHR: 129.37 (-1.86), MCD: 90.62 (-0.35), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
at The Street - Mon Dec 08, 10:04AM CST
Stocks trade flat as a rally in pharmaceuticals trumps a selloff in oil-related companies and plunging crude prices.
VRTX: 118.55 (-2.23), COP: 62.45 (-1.16), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), CBST: 96.31 (+0.04), EBAY: 55.77 (-1.01), RIG: 16.47 (-0.55), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
at The Street - Fri Dec 05, 11:18AM CST
TheStreet's Jim Cramer says Gilead Sciences may finally start to catch up to its peers, based on a research report from J.P. Morgan.
BIIB: 344.49 (+2.16), GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
at The Street - Fri Dec 05, 5:00AM CST
Cramer wants you to avoid Plug Power and Peabody Energy but would buy Molson Coors and Constellation Brands.
BIIB: 344.49 (+2.16), GPRO: 60.52 (+0.47), DRE: 19.30 (-0.27), ALU: 3.35 (-0.08), PLUG: 2.93 (-0.17), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HPQ: 38.01 (-0.46), VTR: 74.44 (+0.77), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), BTU: 7.37 (-0.04), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01)
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Dec 05, 3:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday December 4. Bullish Calls: Constellation Brands (NYSE: STZ ): "That is my favorite. It has Corona and Modelo. It has real magic." ...
GPRO: 60.52 (+0.47), BIIB: 344.49 (+2.16), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), VTR: 74.44 (+0.77), CELG: 114.49 (-2.25), BTU: 7.37 (-0.04), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), CSCO: 26.85 (-0.14), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), BIIB: 344.49 (+2.16), GD: 137.41 (-4.99), GE: 24.89 (-0.52), CAG: 36.73 (-0.56), STKL: 11.04 (-0.29), VTR: 74.44 (+0.77), TWX: 82.12 (-1.19), SBUX: 83.25 (+0.13), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), IDT: 18.09 (-0.33), COST: 137.88 (-3.53), DG: 69.80 (+0.65), GOOGL: 521.51 (-10.60), TRAK: 44.56 (-0.35), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01), AMZN: 307.32 (-0.04), GPRO: 60.52 (+0.47), HD: 99.78 (-0.49), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), FB: 77.83 (+0.10), SLXP: 103.36 (-2.79), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HABT: 41.89 (+0.55), FCAU: 11.36 (+0.18), BMY: 58.75 (-0.93), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), UA: 68.83 (+0.30), BTU: 7.37 (-0.04), LB: 83.39 (+0.24), ESV: 27.04 (-0.80), GILD: 104.13 (-0.18), VALE: 7.19 (-0.07), TXN: 53.11 (-1.38), MRO: 25.45 (-0.80), BAS: 5.22 (+0.05), CVX: 102.38 (-2.53), BABA: 105.11 (+0.14)
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:15AM CST
Shares of Regeneron have been riding high after the company announced that its supplemental biologics license application for Eylea will be reviewed by the FDA on a priority basis.
AMGN: 164.53 (-1.55), AMAG: 40.04 (-0.79), REGN: 416.44 (-7.91)
Ablexis Announces Availability of the AlivaMab Mouse Technology and Settlement of the Litigation with Regeneron Pharmaceuticals, Inc.
Business Wire - Thu Dec 04, 7:00AM CST
Ablexis, LLC today announced the completion and delivery to its licensees of its AlivaMab Mouse technology, an innovative and unique platform for discovery of the next generation of breakthrough human antibody drugs. The delivery of the AlivaMab Mouse technology to licensees earlier in 2014 enabled their deployment of the technology broadly throughout their respective organizations, providing non-exclusive long-term access with no target or field of use limitations, and fulfilling the needs of these companies for an improved transgenic platform for therapeutic antibody discovery. The AlivaMab Mouse technology remains available for non-exclusive licensing and immediate delivery.
REGN: 416.44 (-7.91)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 344.49 (+2.16), HON: 95.88 (-2.01), UTX: 112.15 (-1.89), KMB: 112.68 (-1.36), INTC: 36.22 (-0.48), PVH: 127.03 (+1.47), SLB: 80.00 (-3.01), PEP: 94.74 (-1.55), GWPH: 72.41 (+1.18), EOG: 86.37 (-0.49), REGN: 416.44 (-7.91), CSCO: 26.85 (-0.14), MU: 34.00 (-1.19), SWKS: 69.10 (-0.98), HAL: 37.93 (-0.30), SN: 6.95 (-0.13), BMY: 58.75 (-0.93), BA: 120.77 (-2.60), HPQ: 38.01 (-0.46), CELG: 114.49 (-2.25), ZTS: 41.77 (-1.11), GILD: 104.13 (-0.18), TXN: 53.11 (-1.38), JCP: 6.38 (+0.29), PG: 89.55 (-0.86), PAY: 33.01 (-1.47), SWHC: 9.60 (-0.03)
Jim Cramer on the Stock Market: You Have to Love Biotech
at The Street - Wed Dec 03, 11:29AM CST
In this era of turmoil, investors can take comfort in this sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), AMGN: 164.53 (-1.55), AGIO: 119.56 (+0.36), REGN: 416.44 (-7.91), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
